ANG Lifesciences India Ratios

ANG Lifesciences India Ltd Ratios

The ANG Lifesciences India Ltd Ratios page provides a complete fundamental analysis of ANG Lifesciences India Ltd using key valuation, profitability, and financial strength metrics. Investors tracking ANG Lifesciences India Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

ANG Lifesciences India Ltd (NSE: , BSE: 540694) is currently trading at ₹26.71, with a market capitalization of ₹316.79M. As a major player in the Health technology sector and Pharmaceuticals: major industry, ANG Lifesciences India Ltd remains a key stock for fundamental analysis using ANG Lifesciences India Ltd Ratios.

ANG Lifesciences India Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The ANG Lifesciences India Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in ANG Lifesciences India Ltd Ratios.

Historically, the ANG Lifesciences India Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 6.03
• 2020: 6.33

The decline in ANG Lifesciences India Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The ANG Lifesciences India Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.46.

Historical P/B trend:

• 2024: 0.46
• 2023: 0.77
• 2022: 1.15
• 2021: 2.90

ANG Lifesciences India Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The ANG Lifesciences India Ltd P/S ratio currently stands at 0.32, an important part of ANG Lifesciences India Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.32
• 2023: 0.40
• 2022: 0.45
• 2021: 0.69

A stable or declining ANG Lifesciences India Ltd P/S ratio indicates cautious market sentiment.

ANG Lifesciences India Ltd Price to Cash Flow Ratio (P/CF)

The ANG Lifesciences India Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical ANG Lifesciences India Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 0
• 2022: 6.50
• 2021: 14.26
• 2020: 0

The declining ANG Lifesciences India Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

ANG Lifesciences India Ltd Enterprise Value Ratios

Enterprise Value (EV)

The ANG Lifesciences India Ltd EV currently stands at ₹1.09B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1.09B
• 2023: 1.26B
• 2022: 1.64B
• 2021: 3.14B

ANG Lifesciences India Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The ANG Lifesciences India Ltd EV/EBITDA ratio is currently 400.29, a key metric in ANG Lifesciences India Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 400.29
• 2023: 12.32
• 2022: 10.46
• 2021: 4.59

Higher ANG Lifesciences India Ltd EV/EBITDA suggests premium valuation.

ANG Lifesciences India Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The ANG Lifesciences India Ltd D/E ratio is currently 1.30, reflecting leverage and financial stability.

Historical D/E:

• 2024: 1.30
• 2023: 0.95
• 2022: 0.82
• 2021: 0.92

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The ANG Lifesciences India Ltd ROE currently stands at -17.70%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -17.70
• 2023: -12.48
• 2022: -0.31
• 2021: 64.33

Declining ROE indicates pressure on profitability.

ANG Lifesciences India Ltd Ratios Analysis Summary

The ANG Lifesciences India Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether ANG Lifesciences India Ltd stock is undervalued, fairly valued, or overvalued.

Tracking ANG Lifesciences India Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.